Oleuropein relaxes artery walls the way a calcium-channel blocker does, and slows starch breaking down into sugar in the gut 1. That is why the same extract nudges blood pressure, fasting sugar, and triglycerides together.
The pooled result is a four-to-five-point systolic drop in people whose pressure is already up, smaller or absent in everyone else 1 2. Head-to-head against a real drug, 232 adults on extract fell about as much as those on captopril 3. The largest trial, 621 hypertensive adults, put the extract at 6.4 versus 1.5 on placebo 4.
Blood sugar tells the same story: HbA1c fell in type-2 diabetics 5, and insulin sensitivity rose about 15% in overweight men 6. In people running normal, the effect is zero. It works on metabolism that has started to slip, not on one that is fine.
The bottle is where most people lose. A label reading "olive leaf 500 mg" with no oleuropein percentage tells you nothing about dose; the percentage is the real ingredient list.
Higher dose matters: 500 mg/day did nothing, 1000 mg/day dropped systolic about eleven points 7. Cheap products at unnamed doses are likely too weak to work.
You will not feel this. No energy lift, no mood shift, no sharper afternoons. What you're buying is a slow move in the numbers.
The fine print — when to skip it, and what people get wrong
This is not olive oil in a capsule; the Mediterranean-diet evidence 9 does not carry to the leaf. The "immune booster" line outruns the data: real lab antiviral work 10, no good cold-prevention trial.
It goes nowhere if the product hides its oleuropein percentage, if your pressure and sugar already read normal, or if you use it to dodge a doctor while reading 150/95 — the trial-grade drops can't cover that.
- 1Razmpoosh et al. (2022). The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome. link
- 2Ismail et al. (2021). Olive leaf extract effect on cardiometabolic profile among adults with prehypertension and hypertension: a systematic review and meta-analysis. PeerJ. link
- 3Susalit et al. (2011). Olive (Olea europaea) leaf extract effective in patients with stage-1 hypertension: comparison with Captopril. Phytomedicine. link
- 4Lamti et al. (2025). Efficacy of olive leaf extracts in controlling blood pressure in hypertensive patients: a double-blind randomized clinical trial. Journal of Hypertension. link
- 5Wainstein et al. (2012). Olive leaf extract as a hypoglycemic agent in both human diabetic subjects and in rats. Journal of Medicinal Food. link
- 6de Bock et al. (2013). Olive (Olea europaea L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trial. PLoS One. link
- 7Perrinjaquet-Moccetti et al. (2008). Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins. Phytotherapy Research. link
- 8Lockyer et al. (2017). Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial. European Journal of Nutrition. link
- 9Estruch et al. (2018). Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (PREDIMED). New England Journal of Medicine. link
- 10Salamanca et al. (2021). Anti-influenza virus activity of the elenolic acid rich olive leaf (Olea europaea L.) extract. Antiviral Chemistry and Chemotherapy. link
Olive Leaf Extract (standardised oleuropein)
Standardised extract retails at roughly $30–80/year at clinical dosing (500–1000 mg/day, 20% oleuropein); trivial relative to almost any pharmacological alternative.
One to two capsules daily with food; no titration, no special timing, no lifestyle reorganisation. Trivial.
Multiple convergent small/medium RCTs plus a 621-participant 2025 trial (Lamti 2025) and two meta-analyses (Razmpoosh 2022, Ismail 2021) showing replicable BP and lipid effects in hypertensives. Active-comparator non-inferiority vs captopril (Susalit 2011) is the strongest single trial. No long-term mortality endpoints; no guideline endorsement.
Blood pressure and glucose move within 4–12 weeks in the relevant subgroups (Lockyer 2017, Wainstein 2012, Lamti 2025), with modest secondary improvements in CRP and lipids. Not strongly felt; the effect is biomarker-level, not lived-experience.
A sustained −5 mmHg systolic reduction in hypertensives translates to a modest decade-scale stroke/CHD risk reduction; glycaemic improvement adds. Effect is indirect via surrogate endpoints — no hard mortality trial exists (Razmpoosh 2022, Lamti 2025).